CA19-9 As a Prognostic Biomarker in Pancreatic Neuroendocrine Tumors

#1434

Introduction: Carbohydrate antigen19-9 (CA19-9) is generally not considered as a biomarker in pancreatic neuroendocrine tumors (pNETs) since most pNETs present with normal range of CA19-9.

Aim(s): The current study was to evaluate the role of serum CA19-9 levels as a prognostic factor in a relative large number of patients with pNETs.

Materials and methods: Consecutive patients were retrospectively collected from a single institution between June 2006 and February 2015. The receiver operating characteristic (ROC) curve and area under the ROC curve were used to select the best cut-off values for baseline CA19-9 levels. The primary end point was overall survival. Potential factors related to abnormal elevation of CA19-9 in pNETs were also investigated.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Luo G

Authors: Luo G, Guo M, Liu Z, Liu C, Cheng H,

Keywords: pNET, prognosis, CA19-9, biomarker,

To read the full abstract, please log into your ENETS Member account.